SEC 13F Intelligence

Consonance Capital Management LP / PTGX

Consonance Capital Management LP’s Protagonist Therapeutics Inc Position

Does Consonance Capital Management LP own Protagonist Therapeutics Inc (PTGX)? Not currently — the last reported position was 3.45M shares worth $155M in Q2 2021; the fund’s latest 13F (Q3 2022) no longer reports it.

Position Value
$155M
Q2 2021
Shares
3.45M
% of Portfolio
+18.62%
Quarters Held
4
position exited

Position History PTGX

Reported value by quarter
Q3 ’20: $46MQ3 ’20Q4 ’20: $55MQ4 ’20Q1 ’21: $70MQ1 ’21Q2 ’21: $155MQ2 ’21filingsflow.com
QuarterSharesValue% of Portfolio
Q2 20213.45M$155M+18.62%
Q1 20212.71M$70M+7.48%
Q4 20202.73M$55M+5.14%
Q3 20202.37M$46M+5.64%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Consonance Capital Management LP’s full portfolio or all institutional holders of PTGX.